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Introduction: Dementia with Lewy bodies (DLB) and Corticobasal Syndrome (CBS) are atypical parkinsonian disorders
with fronto-subcortical and posterior cognitive dysfunction as common features. While visual hallucinations are a good
predictor of Lewy body pathology and are rare in CBS, they are not exhibited in all cases of DLB. Given the clinical
overlap between these disorders, neuropsychological and imaging markers may aid in distinguishing these entities.
Methods: Prospectively recruited case–control cohorts of CBS (n =31) and visual hallucination-free DLB (n =30),
completed neuropsychological and neuropsychiatric measures as well as brain perfusion single-photon emission
computed tomography and structural magnetic resonance imaging (MRI). Perfusion data were available for forty-two
controls. Behavioural, perfusion, and cortical volume and thickness measures were compared between the groups to
identify features that serve to differentiate them.
Results: The Lewy body with no hallucinations group performed more poorly on measures of episodic memory
compared to the corticobasal group, including the delayed and cued recall portions of the California Verbal Learning
Test (F (1, 42) =23.1, P <0.001 and F (1, 42) =14.0, P =0.001 respectively) and the delayed visual reproduction of the
Wechsler Memory Scale-Revised (F (1, 36) =9.7, P =0.004). The Lewy body group also demonstrated reduced perfusion
in the left occipital pole compared to the corticobasal group (F (1,57) =7.4, P =0.009). At autopsy, the Lewy body cases
all demonstrated mixed dementia with Lewy bodies, Alzheimer’s disease and small vessel arteriosclerosis, while the
corticobasal cases demonstrated classical corticobasal degeneration in five, dementia with agyrophilic grains + corticobasal
degeneration + cerebral amyloid angiopathy in one, Progressive Supranuclear Palsy in two, and Frontotemporal Lobar
Degeneration-Ubiquitin/TAR DNA-binding protein 43 proteinopathy in one. MRI measures were not significantly
different between the patient groups.
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Conclusions: Reduced perfusion in the left occipital region and worse episodic memory performance may help to
distinguish between DLB cases who have never manifested with visual hallucinations and CBS at earlier stages of the
disease. Development of reliable neuropsychological and imaging markers that improve diagnostic accuracy will
become increasingly important as disease modifying therapies become available.Introduction
Dementia with Lewy Bodies (DLB) and Corticobasal Syn-
dome (CBS) are atypical parkinsonian disorders associated
with fronto-subcortical and posterior cognitive dysfunc-
tion. Pathologically, DLB is an α-synucleinopathy with
many cases having concomitant Alzheimer’s pathology [1].
CBS is more heterogeneous with the following underlying
pathological substrates observed: corticobasal degener-
ation (CBD) , progressive supranuclear palsy (PSP), fronto-
temporal lobar degeneration (FTLD)-Tau (Pick’s disease)
and FTLD-Ubiquitin/TAR DNA binding protein (TDP-
43), Alzheimer’s disease (AD) and, rarely, DLB [2-6]. In a
small case series of pathologically proven CBD, one pa-
tient had a differential diagnosis of CBS versus DLB and
was eventually confirmed to have CBD at autopsy [7].
Clinically, DLB is characterized by recurrent visual halluci-
nations, spontaneous parkinsonism, fluctuating attention
and alertness as well as executive and visuospatial dys-
function [8,9]. ‘Classical’ CBS is characterized by asym-
metric rigidity, apraxia, dystonia, myoclonus, alien-limb
phenomenon and/or cortical sensory loss [10]; however,
dementia is often the initial presentation and classical fea-
tures may emerge only later in the disease course [11].
While the two disorders can usually be distinguished on
clinical grounds in the mid-stages of the disease course,
the early stages often have overlapping clinical features
and accurate diagnosis is more challenging especially
when not all features are present.
The diagnostic criteria for DLB have demonstrated
greater specificity (95%) than sensitivity (83%) [12]; other
studies have reported even less successful figures [13,14].
While visual hallucinations are exceptionally rare in CBS
[15], they have been shown to be the most sensitive and
specific predictor of DLB pathology [16]. However, the
prevalence of visual hallucinations ranges between 30% to
80% of pathologically proven DLB cases, indicating a low
negative predictive value [9]. Recognizing and diagnosing
DLB presenting without visual hallucinations early on and
distinguishing it from CBS and other atypical parkinsonian
syndromes has direct clinical relevance. For example, the
symptoms of DLB have been shown to respond well to
cholinesterase inhibitors [17,18], while patients with fron-
totemporal dementia spectrum disorders that includes
CBS, do not benefit cognitively and may be more prone to
behavioural disturbance on this class of drugs [19]. As
such, additional data made available by neuroimaging andneuropsychological assessment may help to best differenti-
ate DLB without visual hallucinations from CBS and this
could allow clinicians to better target symptomatic therapy
and avoid unwanted side effects. Furthermore, understand-
ing differences between these two parkinsonian disorders
using neuroimaging and neuropsychological evaluation
may also shed light onto pathological correlates.
The objectives of this study were to compare: 1) the ini-
tial clinical and standardized neuropsychological and
neuropsychiatric profile of a prospective cohort of 30 DLB
patients with no history of visual hallucinations (visual
hallucination-free [VHF]-DLB) and 31 CBS patients ascer-
tained from both a movement disorders clinic and a cog-
nitive neurology clinic; and 2) the perfusion single-photon
emission computed tomography (SPECT) and structural
magnetic resonance imaging (MRI) imaging features of
CBS and VHF-DLB patients to elucidate functional and




Thirty participants meeting clinical criteria for possible
(n =10) or probable DLB (n =20) [9] without any history
of visual hallucinations were recruited through the Linda
C. Campbell Cognitive Neurology Research Unit at
Sunnybrook Health Sciences Centre. Thirty-one partici-
pants with a clinical diagnosis of CBS according to diagnos-
tic criteria proposed by Boeve et al. [20] were recruited
through the former clinic and the Movement Disorders
Centre at the Toronto Western Hospital, University Health
Network. Diagnoses were made by consensus agreement by
at least two reviewing neurologists with expertise in neuro-
degenerative diseases (MM, AEL and/or SEB). This study
also included 42 healthy controls with available SPECT
data; 30 of them were matched to the VHF-DLB group (11
were unique to this group and 19 overlapped with the CBS
control group) while 31 were matched to the CBS group
(12 were unique to this group and 19 overlapped with the
VHF-DLB control group). Controls were selected to match
as closely as possible for age, sex and years of education for
each patient group. Subjects had to have a SPECT scan
completed and available for analysis to be included in the
study. Subjects needed to be within the age range of 40 to
90, have contact with a primary caregiver on at least four
days per week, were sufficiently literate and fluent in
Misch et al. Alzheimer's Research & Therapy 2014, 6:71 Page 3 of 15
http://alzres.com/content/6/9/71English, and their SPECT and neuropsychological evalua-
tions were completed within a consecutive three-month
period. Exclusion criteria were: presence of secondary/
reversible causes of dementia which were untreated, con-
comitant neurological or psychiatric illness/substance use
and abuse, history of significant head trauma, as well as le-
sions on MRI indicating another pathological condition. The
majority of the VHF-DLB, CBS and normal controls were
recruited and monitored as part of the Sunnybrook De-
mentia Study (ClinicalTrials.gov identifier: NCT01800214), a
prospective longitudinal study of dementia and ageing.
Seven of the VHF-DLB patients were recruited through
a prospective pharmacogenetic study of cholinesterase
inhibitor response in Lewy body spectrum disorders
(ClinicalTrials.gov identifier: NCT01944436), which em-
ployed similar imaging and clinical assessments as the
Sunnybrook Dementia Study. Both studies were approved
by the local Research Ethics Boards at Sunnybrook Health
Sciences Centre and the Toronto Western Hospital,
University Health Network. Written informed consent was
obtained from the participants or their substitute decision
makers in accordance with the Declaration of Helsinki.
Neuropsychological, neuropsychiatric and functional
measures
Neuropsychological tests assessing general intelligence and
cognition included Folstein’s Mini-Mental State Examin-
ation (MMSE) [21]; the Mattis Dementia Rating Scale
(DRS) [22]; the Clock Drawing Test [23]; the National
Adult Reading Test-Revised (NART-R) [24]; and Raven’s
Progressive Matrices [25]. Tests assessing learning and
episodic verbal memory included the California Verbal
Learning Test (CVLT) [26], while the visual reproduction
subtest of the Wechsler Memory Scale-Revised (WMS-R)
assessed visual memory [27]. Measures of language func-
tion and naming included: the Boston Naming Test (BNT)
[28]; semantic/categorical fluency [29]; and the comprehen-
sion subscale of the Western Aphasia Battery (WAB) [30].
Initially, the full WAB was given to all patients, but in the
last few years it has only been administered if there was
anomia detected on the BNT [30]. Facial and limb praxis
was assessed using the WAB praxis subscale [30]. Attention
and working memory was assessed using the Forward and
Backward Digit Span tests from the WMS-R [27,31].
Several assessments of executive function were employed
including: phonemic (F-, A-, and S-word) fluency [27,29];
the Trail Making Test A and B (TMT-A and -B) [27]; and
the Wisconsin Card Sort Test (WCST) [32]. Visuospatial
function was assessed using the Rey-Osterrieth Complex
Figure Test [27,33,34] and the Benton Line Orientation
task, which is motor-free and assesses visuospatial orienta-
tion and attention [27]. Behavioural function was investi-
gated using the Neuropsychiatric Inventory (NPI-12) [35].
Severity of depressive symptoms was assessed using theCornell Scale for Depression in Dementia (CSDD) [36].
Functional assessment was performed using the Disability
Assessment for Dementia (DAD), which assesses both basic
and instrumental activities of daily living including subcom-
ponents of initiation, planning and performance [37].
Brain SPECT acquisition and processing
SPECT imaging employed a triple-head gamma camera
(Prism 3000XP; Phillips Medical Systems Inc., Cleveland,
OH, USA) and was performed between 30 and 120 minutes
after injection of 20 mCi (740 MBq) of Technetium-99 m
ethyl cysteinate dimer (99mTc-ECD SPECT). Patients were
asked to rest with their eyes open during the injection
phase in a quiet room. A total of 120 views were acquired
uniformly over 360 degrees using all three detectors fitted
with ultra-high resolution fan-beam collimators. Each
view consisted of a 128 × 128 pixel image. Imaging time
was 19 minutes. A ramp-filtered back-projection algorithm
followed by a three-dimensional restoration post-filter was
employed for image reconstruction (Wiener filter, multi-
plier 1.0). Reconstructed image resolution was 9.7 mm full
width at half maximum (FWHM). Ellipses were fit to the
approximate location of the head outline in each transaxial
image and a calculated attenuation correction applied [38].
Voxel dimensions were 2.18 × 2.18 × 3.56 mm.
Brain MRI acquisition, processing and region of interest
cortical volumetric/thickness assessment
MRI acquisition
Structural MRI was obtained in 29 of the 31 CBS patients
and 25 of the 30 VHF-DLB patients using a standard proto-
col. Images were acquired on a 1.5 T Signa MR imager (GE
Medical Systems, Milwaukee, WI, USA) and consisted of
the following acquisitions: 1) T1-weighted (axial three-
dimensional spoiled gradient (SPGR) echo, with echo time
(TE) 5 ms, repetition time (TR) 35 ms, flip angle 35°, num-
ber of excitations (NEX) 1, field of view (FOV) 22 ×
16.5 cm, in-plane resolution 0.859 × 0.859 mm and slice
thickness 1.2 to 1.4 mm); 2) proton-density (PD); and 3)
T2-weighted images (interleaved axial spin echo, with TEs
30 and 80 ms, TR 3 s, NEX 0.5, FOV 20 × 20 cm, in-plane
resolution 0.781 × 0.781 mm and slice thickness 3 mm).
Brain extraction and automated tissue segmentation
Twenty-one of the 29 CBS scans and 23 of the 25 VHF-
DLB scans were of sufficient quality to undergo semi-
automated image analysis. Poor image quality was primarily
due to head motion artifacts. Brain extraction and auto-
mated tissue segmentation were based on previously de-
scribed methods [39,40]. Images were co-registered to the
T1-weighted image using the Functional Magnetic Reson-
ance Imaging of the Brain (FMRIB) Software Library’s
(FSL) flirt tool and a normalised mutual information cost
function [41]. Proton density (PD)/T2 images were used
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brospinal fluid (CSF), then the masked T1 was segmented
using a T1-based protocol whereby local intensity histo-
grams are fitted to four Gaussian curves to derive cut-offs
for classifying each voxel as white matter, grey matter or
CSF [39]. This is important for calculating the total intra-
cranial volume in correcting for head size, especially in
focal atrophy syndromes, such as CBS. Lesion Explorer was
then used to further segment tissue that appears hyperin-
tense on PD and T2 and a trained rater manually checked
the lesion mask and corrected false positives/negatives [40].
This lesion mask was then overlaid onto the segmented
brain to identify the four lesion classes (periventricular
subcortical hyperintensities and black holes, as well as
deep subcortical hyperintensities and black holes) based
on three-dimensional location and T1 intensity [40].
FreeSurfer cortical thickness and volume calculations
The FreeSurfer cortical parcellation procedure was subse-
quently applied to the fully segmented Lesion Explorer
scans. The boundary between white and grey matter was
corrected for topological defects [42] and deformed out-
ward in order to locate the pial surface and achieve the
final thickness estimations [43]. A region of interest (ROI)
gyral atlas was then applied to obtain cortical thickness
(mm) and volume (mm3) measurements in 34 bilateral
gyral ROIs [44].
Statistical parametric mapping SPECT analysis
SPECT scans were converted to Analyze 7.5 format. Statis-
tical Parametric Mapping version 5 (SPM5, Wellcome
Department of Imaging Neuroscience, University College
London, London, UK) was used for all imaging processing.
Images were spatially normalised to a standard SPECT
template in Montreal Neurological Institute (MNI) space
[45] with re-sampling of voxel dimensions of 2 × 2 ×
2 mm. Images were then smoothed spatially using an iso-
tropic Gaussian kernel (12 mm FWHM). Proportional
scaling was used to normalise image intensity values be-
tween subjects, thus reducing the chances that inter-
subject variability in cerebral tracer uptake would influ-
ence regional perfusion changes. The cerebellum is fre-
quently used to normalise SPECT counts in studies of
dementia [45] and was shown to be the region of choice
for normalisation in DLB and AD [46]. However, crossed
cerebellar diaschisis may lead to relative differences in per-
fusion between the left and right cerebellar hemispheres,
and if the whole cerebellum is used as the reference region
in these cases, regional cerebral blood flow (rCBF) may be
miscalculated. We, therefore, applied the following rule: if
there was more than a 5% difference in counts between
left and right cerebellar hemispheres, the hemisphere with
the higher perfusion count was used as the reference re-
gion. If the hemispheric difference was less than 5% thenthe average count in the whole cerebellum was used as the
reference region.
Voxel-by-voxel analyses were performed using un-
paired t-tests to compare CBS to controls, and VHF-
DLB to controls. Covariates were incorporated if they
were found to be significantly different between groups.
We reported significance using a voxel-wise P-value
threshold (P <0.05) corrected for multiple comparisons
and an extent threshold of at least 20 contiguous voxels
(kE ≥20). Our correction methodologies included con-
trolling the family-wise error (FWE) rate [47] and con-
trolling the false discovery rate (FDR) [48]. Controlling
the FWE rate is more conservative, but is known to be
associated with type II errors. A whole brain mask was
used to exclude extracranial voxels from the analysis.
The maximal peak coordinates of the perfusion differ-
ences were converted to Talairach space using the Yale
Non-linear MNI to Talairach Converter [49,50]. These
converted coordinates were translated into anatomical
brain regions and Brodmann Areas (BAs) using Talairach
Daemon Client [51,52].
Region of interest SPECT method
The second phase of the SPECT imaging analyses set out
to identify regions of perfusion difference between the
VHF-DLB group and the CBS group. A ROI analysis was
performed using selected candidate brain regions that
were found to show reduced perfusion in the case versus
control analysis, but that did not overlap between the CBS
and VHF-DLB groups (Figure 1). Reconstructed SPECT
images were co-registered to a template that was an aver-
age of 14 healthy, elderly control scans. A T1-weighted
MRI with dimensions similar to the SPECT template was
the source of 79 bilateral ROIs as previously described
[53]. To obtain ROI intensity values, we used a common
transformation to move from the SPECT template space
to MRI space. The cerebellum was used as the reference
region in a manner similar to that described in the SPM
analysis to generate semi-quantitative perfusion ratios in
each ROI [53].
Demographic, clinical, neuropsychological, SPECT ROI and
MRI ROI cortical volumetric and thickness data analysis
Statistical analysis of demographic, clinical, neuropsycho-
logical and ROI SPECT variables was performed using the
Statistical Package for the Social Sciences (SPSS), version
16. Categorical demographic and clinical data were ana-
lysed using chi-square or Fisher exact tests. The normality
of continuous demographic, neuropsychological and ROI
SPECT and MRI data was assessed based on examination
of Q-Q probability plots. Normally distributed data were
analysed using independent sample t-tests or univariate
analysis of covariance (ANCOVA). Mann Whitney U tests
were performed for non-normally distributed data.
Figure 1 Regions of interest (ROIs) that show differential perfusion in the case versus control analyses. Views are shown in standard
radiological orientation.
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Multivariate ANCOVA (MANCOVA) was used to com-
pare perfusion ratios within the identified candidate
ROIs between the VHF-DLB and CBS groups. Covariates
were included if they were found to be different between
the groups being compared. We subsequently performed
an SPM analysis comparing the VHF-DLB group to the
CBS group to confirm the findings of our ROI approach.
MRI analysis
Independent samples t-tests were performed with cortical
ROI volumes and thickness included as dependent variables
and with group (that is, CBS versus VHF-DLB) as the inde-
pendent variable. ROI volume and thickness measurements
that showed significant between group differences on the t-
tests were then incorporated into a MANCOVA model asTable 1 Demographics of patients with corticobasal syndrom
(VHF-DLB) and respective matched control groups
Demographic and clinical features CBS
(number =31)
Gender 19 F 12 Ma
Handedness 29R 2 L
Age of onset (mean ± SEM years) 64.7 ± 1.6
Age at investigation (mean ± SEM years) 68.5 ± 1.7
Duration of symptoms (mean ± SEM years) 3.8 ± 0.4
Years of education (mean ± SEM years)b 12.4 ± 0.6bc
Body side most affected 16R 15 L
aFisher’s Exact Test, P =0.01; bt[60] = −2.7, P =0.008; ct[60] =2.4, P =0.02. F, female; Ldependent variables and with group (that is, CBS versus
VHF-DLB) as the independent variable. The following co-
variates were included: sex, years of education and total
intracranial volume. A post-hoc Bonferroni correction pro-
cedure was applied to adjust for effects of multiple testing.
Logistic regression analysis
Neuropsychological and imaging measures that were
found to be different between the CBS and VHF-DLB
groups were then entered as independent variables into
a logistic regression model with group membership as
the dependent variable.
Pathological assessment
Three DLB and nine CBS cases came to autopsy. The
brains were prepared according to standard neuropathologice (CBS), non-hallucinating dementia with Lewy bodies
CBS controls VHF-DLB VHF-DLB controls
(number =31) (number =30) (number =30)
19 F 12 M 10 F 20 Ma 10 F 20 M
29R 2 L 29R 1 L 28R 2 L
N/A 68.6 ± 1.3 N/A
70.0 ± 1.2 72.3 ± 1.7 73.1 ± 1.2
N/A 3.7 ± 0.4 N/A
14.5 ± 0.5b 14.6 ± 0.7c 15.17 ± 0.6
N/A N/A N/A
, left; M, male; N/A, not applicable; R, right; SEM, standard error of the mean.
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Stains and immunostains included Luxol Fast Blue-
Hematoxylin and Eosin (LFB-H & E), hyperphosporylated
Tau, beta-amyloid, ubiquitin, alpha-synuclein, p62, glial fi-




The demographic characteristics of the VHF-DLB, CBS
and their respective control groups are shown in Table 1.
Years of education was used as a covariate in the SPECT
comparison of CBS versus controls because it was higher
in the control group. Years of education and sex were used
as covariates in all analyses relating to the comparison be-
tween the CBS and VHF-DLB groups given that they were
different between the two patient groups and given that
perfusion differences between men and women have been
previously demonstrated using 99mTc-ECD SPECT [54].
Clinical and pathological features
Table 2 displays the clinical features of the DLB cohort at
the time of entry into the study. Of the ten cases of possibleTable 2 Clinical characteristics of patients with VHF-DLB
at the time of entry into the study





Parkinsonism 26 (86.7) 30 (100%)a
Rigidity 24 (80.0) -
Gait disturbance 21 (70.0) -
Bradykinesia 20 (66.7) -
Tremor 17 (56.7) -
Postural instability 15 (50.0) -
Hypomimia 15 (50.0) -
Fluctuating cognition 18 (60.0) 18 (60.0)




7 (23.3) 7 (23.3)
Neuroleptic sensitivity 3 (10.0) 3 (10.0)b
Suggestive features
Depressive symptoms 14 (46.7) 14 (46.7)
Systematised delusions 7 (23.3) 7 (23.3)
Orthostatic hypotension 5 (16.7) 5 (16.7)
Non-visual hallucinations 5 (16.7) 5 (16.7)
Syncope 1 (3.3) 1 (3.3)
aAll patients developed parkinsonism within one year of investigation;
bneuroleptic use avoided given DLB diagnosis. Only three patients were
exposed to an antipsychotic and all had sensitivity. N, number; REM, rapid eye
movement; VHF-DLB, visual hallucination-free dementia with Lewy bodies.DLB, eight presented with spontaneous parkinsonism and
dementia while two presented with fluctuating attention/
alertness and dementia. Of the 20 cases of probable DLB,
ten presented with parkinsonism and marked fluctuations
in attention and alertness; four exhibited parkinsonism,
fluctuating attention/alertness and rapid eye movement
(REM) sleep behaviour disorder; two exhibited parkinson-
ism and REM sleep behaviour disorder; two exhibited par-
kinsonism and neuroleptic sensitivity; one presented with
fluctuating attention/alertness and REM sleep behavior dis-
order; and one exhibited fluctuating attention/alertness and
REM sleep behavior disorder, all in the context of dementia.
Of the core diagnostic features of DLB, parkinsonism was
the most common at presentation (87%, 26/30 patients).
Importantly, all DLB subjects went on to develop parkin-
sonism within one year of the initial investigation. As a re-
sult, two possible DLB cases met criteria for probable
disease on longitudinal assessment bringing the total num-
ber of probable cases to 22. Of the parkinsonian features,
rigidity and gait disturbance were the most prevalent.
Fluctuating attention and alertness, also a core diagnostic
feature was found in 60% (18/30) of the subjects. Visual
hallucinations were not observed in this DLB cohort, which
was the basis for their inclusion in this study. Nineteen of
the 30 VHF-DLB patients were on cholinesterase inhibitors
at the time of this study. However, none had exhibited vis-
ual hallucinations prior to initiation of therapy.
The clinical features of the CBS group are shown in
Table 3. Asymmetric apraxia (90%; 28/31) and rigidity
(90%; 28/31) were the most common features in thisTable 3 Clinical characteristics of CBS sample
Clinical
characteristics






Rigidity (asymmetric) 28 (90.3%) 31 (100%)
Dystonia 16 (51.6%) 18 (58.1%)
Levodopa trial with
poor responsea
13 (41.9%) 13 (41.9%)
Tremor – postural/
action
8 (25.8%) 11 (35.6%)
Cortical features
Apraxia 28 (90.3%) 31 (100%)
Cortical sensory loss 19 (61.3%) 19 (61.3%)
Alien-limb
phenomenon
1 (3.2%) 3 (9.7%)
Limb levitation 7 (22.6%) 10 (32.3%)
Myoclonus 9 (29.0%) 13 (41.9%)
Early dementia 22 (71.0%) 22 (71.0%)
Language disturbance 24 (77.4%) 24 (77.4%)
aThirteen patients had a trial of levodopa and all responded poorly based on
clinical assessment. Average time for emergence of additional symptoms or
signs on follow-up was 1.0 ± 0.3 years. CBS, corticobasal syndrome; N, number.
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24/31) and early dementia (71%; 2/31). Sixteen patients
(51.6%) presented with the right side of their body most
affected while 15 (48.4%) had a left-sided presentation.
We retrospectively applied the new diagnostic criteria
for CBS [55]. Sixteen of our CBS cases met the new cri-
teria for probable CBS while 15 met possible criteria.
Figure 2 demonstrates the frequency of the core signs
and symptoms of each of the clinical diagnostic categor-
ies across both the VHF-DLB and CBS groups. As ex-
pected based on the design of this study, there were
several differences in the frequency of clinical signs and
symptoms between the VHF-DLB and CBS groups. Spe-
cifically, asymmetry of the apraxia and/or motor signs,
and presence of apraxia, dystonia, myoclonus and cor-
tical sensory loss were more frequent in the CBS group.
There were no differences between the presence of par-
kinsonism or true alien limb phenomenon noted al-
though the latter was an uncommon feature in our CBS
group. The VHF-DLB group had a higher occurrence of
early cognitive impairment, fluctuations in attention
and/or alertness and the presence of REM behavioral
disorder.
Subsequent pathology was obtained in three subjects in
the VHF-DLB group, all of whom had pathological con-
firmation of Lewy body disease with all demonstrating
concomitant Alzheimer’s pathology and small vessel ar-
teriosclerosis. Nine subjects in the CBS group came to
autopsy with pathological diagnoses of pure CBD in five,
mixed disease - dementia with agyrophilic grains + CBD+
cerebral amyloid angiopathy in one, PSP in two, and
FTLD-U/TDP43 proteinopathy due to mutation in theFigure 2 Bar graph comparing frequency of core signs and symptom
corticobasal syndrome; VHF-DLB, visual hallucination-free dementia with Leprogranulin gene (GRN) in one [56]. None of the CBS
cases had Lewy bodies, Lewy neurites or other alpha-
synuclein positive inclusions.Neuropsychological data
The complete neuropsychological, neuropsychiatric and
functional profiles of both patient groups are shown in
Table 4. The CBS and VHF-DLB groups did not differ on
the MMSE or DRS. After controlling for effects of sex and
years of education, the VHF-DLB group demonstrated
more marked impairment compared to the CBS group on
the CVLT-long delay free recall (mean ± SEM =2.4 ± 0.5
versus 6.6 ± 0.6, respectively; F (1,42) =23.1, P <0.001) and
CVLT-long delay cued recall (mean ± SEM =3.9 ± 0.5
versus 7.4 ± 0.6, respectively; F (1,42) =14.0, P =0.001) as
well as the WMS-R delayed visual reproduction (mean ±
SEM =4.2 ± 1.2 versus 10.5 ± 2.3, respectively; F (1,36) =9.7,
P =0.004). Because of the observed CVLT differences, we
performed secondary analyses to determine if the impair-
ments seen in the VHF-DLB group on recall were due to
encoding or retrieval deficits. Both groups demonstrated a
similar benefit from cueing on the CVLT (data not shown).
However, using the sum of the total number of words
retained after each learning trial (one through five), the
VHF-DLB group was found to perform more poorly on en-
coding than the CBS group (VHF-DLB: 21.6 ± 2.4 versus
CBS: 31.3 ± 2.0; F (1,42) =8.5, P =0.006).SPM and ROI SPECT analysis
Figure 3 shows the voxel clusters for which a significant
reduction in perfusion in the CBS and VHF-DLB groupss in the CBS versus VHF-DLB groups. *P <0.005; ▲P <0.05. CBS,
wy bodies.
Table 4 Mean (± SEM) scores on neuropsychological,
neuropsychiatric and functional measures in the CBS and
VHF-DLB groups
Psychometric measures CBS (number) VHF-DLB (number)
General cognition
MMSE/30 (number =59) 21.7 ± 1.2 (31) 22.1 ± 1.1 (28)
Clock Drawing Test/10
(number =26)
6.9 ± 0.8 (9) 7.7 ± 0.6 (17)
NART/127.8 (number =38) 107.5 ± 1.9 (19) 108.4 ± 2.1 (19)
Raven’s Progressive
Matrices (number =40)
21.9 ± 1.6 (22) 21.2 ± 1.3 (18)
DRS/144 (number =53) 113.5 ± 4.1 (26) 114.6 ± 3.7 (27)
Memory
CVLT Long Delay Free
Recall/16 (number =46)a
6.6 ± 0.6 (21) 2.4 ± 0.5 (25)
CVLT Long Delay Cued
Recall/16 (number =46)a
7.4 ± 0.6 (21) 3.9 ± 0.5 (25)
Delayed Visual Reproduction
/41 (number =40b
10.5 ± 2.3 (19) 4.2 ± 1.2 (21)
Language
WAB total/100 (number =38) 85.7 ± 2.5 (23) 86.5 ± 2.2 (15)
Boston Naming/30
(number =47)
24.0 ± 1.0 (22) 22.5 ± 1.1 (25)
Semantic Fluency/20
(number =53)
9.8 ± 1.2 (26) 10.3 ± 1.0 (27)
Praxis
WAB praxis/60 (n =48) 53.2 ± 1.6 (27) 55.6 ± 0.6 (21)
Attention and working
memory
Digit span - forward/12
(number =50)
7.0 ± 0.6 (23) 6.8 ± 0.5 (27)
Digit span - backward/12
(number =50)




17.0 ± 3.0 (20) 18.5 ± 2.3 (25)
Benton Line Orientation
/30 (number =44)




19.1 ± 2.7 (21) 22.1 ± 3.2 (26)
Trail Making Test A (time in
seconds) (number =42)
108.7 ± 14.7 (19) 101.4 ± 11.5 (23)
Trail Making Test B (time in
seconds) (number =31)




Categories 0 to 1: Counts (%) 11 (50%) 17 (77%)
Categories 2 to 4: Counts (%) 11 (50%) 5 (23%)
WCST perseverative errors
(number =44)
11.7 ± 2.9 (22) 19.8 ± 3.4 (22)
Table 4 Mean (± SEM) scores on neuropsychological,










12.1 ± 2.5 (29) 10.5 ± 2.4 (26)
Functional measures
DAD (%) (number =57) 68.8 ± 5.7 (30) 78.9 ± 4.1 (27)
aP <0.005; bP <0.05. The number of patients tested is listed next to individual
measures. Missing data are secondary to the inability of the patient to
complete the test. CBS, corticobasal syndrome; CVLT, California Verbal
Learning Test; DAD, Disability Assessment Scale for Dementia; DRS, Mattis
Dementia Rating Scale; FAS, F-, A-, and S-phonemic fluency; MMSE, Folstein’s
Mini-Mental State Exam; NART, National Adult Reading Test; SEM, standard
error of the mean; VHF-DLB, visual hallucination-free dementia with Lewy
bodies; WAB, Western Aphasia Battery; WCST, Wisconsin Card Sort Test.
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revealed significant reductions in perfusion after correct-
ing the FWE (most conservative) in the right superior
frontal gyrus and left middle frontal gyrus in the CBS
group relative to controls (Table 5). Analysis after correct-
ing the FDR (less conservative) revealed bilateral hypoper-
fusion in the medial and dorsolateral frontal area, and
parietal regions in the CBS groups relative to controls
(Table 5). The VHF-DLB group demonstrated significant
reductions in the left and right middle temporal gyri, right
superior parietal lobule, left precuneus, left superior tem-
poral gyrus, left inferior parietal lobule and left middle oc-
cipital gyrus relative to controls (FWE-corrected) (See
Table 6). Less conservative correction methods using the
FDR revealed the same regions of reduced perfusion as
demonstrated by FWE-correction methods in addition to
symmetrical, bilateral hypoperfusion in frontal and tem-
poral regions and in the left caudate in VHF-DLB com-
pared to controls (Table 6). There were no areas of
increased perfusion seen in the controls relative to both
patient groups.
We then examined for perfusion differences between the
VHF-DLB and CBS groups directly using the pre-specified
hypothesis that areas differentiating the two patient groups
will reside within non-overlapping regions of reduced per-
fusion identified in their respective case versus control
comparisons (Figure 1). Using a MANCOVA model con-
trolling for effects of sex and years of education with the in-
dependent variable being patient group and the dependent
variables being perfusion ratios in ROIs, the left occipital
pole was found to be the only ROI showing reduced perfu-
sion in the VHF-DLB patients compared to the CBS group
(F (19,39) =2.66, P =0.005; Wilk’s Λ =0.44, partial η2 =
0.56). The corrected mean perfusion ratio ± SEM for the
VHF-DLB group was 0.80 ± 0.02 versus 0.88 ± 0.02 for the
Figure 3 Statistical Parametric Map (SPM) depicting regions of decreased perfusion in A) VHF-DLB and B) CBS relative to controls. Red
areas are corrected for multiple testing using the False Discovery Rate, while green areas are corrected using the more conservative Family Wise
Error method. Views are shown in standard anatomical orientation.
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univariate analysis)). No other ROIs showed differential
perfusion between the patient groups. This finding was
subsequently confirmed using SPM. Specifically, after con-
trolling for the effects of years of education and sex in
SPM, the left cuneus (Brodmann Area 18; Talairach co-
ordinates x = −14, y = −96, and z =4; number of voxels in
the cluster =159) was found to show reduced perfusion in
the VHF-DLB group compared to the CBS group (SPM
t-score =3.9, P <0.001 [uncorrected]).
MRI ROI cortical volumetric and thickness analysis
Several bilateral cortical ROI volume measures and one
cortical ROI thickness measure within frontal, temporal
and parietal regions were found to be reduced in the CBS
group compared to the VHF-DLB group in the independ-
ent samples t-test analysis. These ROI volumetric and
thickness measures were incorporated into a MANCOVA
analysis and the overall model that controlled for sex,
years of education, and total intracranial volume did not
show any statistically significant differences between the
VHF-DLB and CBS groups with respect to cortical ROI
volume and thickness measures.
Logistic regression predicting group membership
A logistic regression was performed to determine the ef-
fects of CVLT-long delay free recall score and perfusion
within the left occipital pole on predicting patient groupmembership (that is, VHF-DLB versus CBS). So as to not
violate the assumption of independence of observations
required for logistic regression, the CVLT-long delay cued
recall and WMS-R delayed visual reproduction were not
included in this model because they were strongly corre-
lated with the CVLT-long delay free recall (data not
shown). The overall logistic regression model was statisti-
cally significant (χ2 [2] =23.7, P <0.0005). The model cor-
rectly classified 80.4% of cases and accounted for 53.9%
(Nagelkerke R2) of the variance in patient group member-
ship. CVLT-long delay free recall was the only independ-
ent variable that correctly predicted group membership
(Wald test [1] =10.7, P =0.001). Specifically, worse per-
formance on this memory test was associated with an in-
creased likelihood of belonging to the VHF-DLB group.
Discussion
This study demonstrated that neuropsychological mea-
sures assessing both verbal and visual episodic memory
combined with perfusion in the left occipital region may
be useful in distinguishing between VHF-DLB and CBS.
Specifically, we have found that the VHF-DLB group per-
formed worse on the CVLT long delay free and cued recall
as well as on the WMS-R delayed visual reproduction task
and showed decreased perfusion in the left occipital pole
ROI compared to CBS patients. However, in a logistic re-
gression analysis, the CVLT long delay free recall scores
had better predictive value than left occipital pole
Table 5 Areas of relative hypoperfusion on SPECT when CBS compared to their respective control groups
Anatomical locus (Brodmann
area)
Talairach coordinates Number of voxels SPM t-score (P-value)
x y z
CBS versus controls (FWE-corr)
Right middle frontal gyrus (6) 50 8 42 236 5.4 (P =0.003)
Left superior frontal gyrus (6) −18 9 70 99 5.4 (P =0.005)
CBS versus controls (FDR-corr)
Right middle frontal gyrus (6) 50 8 42 1791 5.4 (P =0.005)
Right superior frontal gyrus (6) 6 7 70 4.7 (P =0.007)
Right sub-gyrus (6) 30 −1 55 4.0 (P =0.014)
Left superior frontal gyrus (6) −18 9 70 850 5.4 (P =0.005)
Left superior frontal gyrus (6) 0 −2 68 3.5 (P =0.020)
Left middle frontal gyrus (6) −26 −1 50 3.6 (P =0.019)
Left precentral gyrus (9) −34 9 31 203 4.4 (P =0.009)
Left precuneus (7) −2 −57 62 655 4.4 (P =0.009)
Right precuneus (7) 4 −53 65 4.4 (P =0.010)
Left postcentral gyrus (7) −4 −51 67 3.7 (P =0.017)
Left superior parietal lobule (7) −34 −53 60 834 4.1 (P =0.013)
Left superior parietal lobule (7) −32 −46 47 3.8 (P =0.017)
Left postcentral gyrus (2) −30 −37 70 4.0 (P =0.015)
Right postcentral gyrus (2) 34 −35 68 213 4.1 (P =0.013)
Right postcentral gyrus (2) 48 −27 40 163 3.9 (P =0.015)
Right inferior frontal gyrus (47) 44 17 −3 96 3.8 (P =0.016)
Right superior frontal gyrus (10) 32 57 23 31 3.8 (P =0.017)
Right superior parietal lobule (7) 32 −59 58 67 3.7 (P =0.017)
CBS, corticobasal syndrome; FDR-corr, corrected for False Discovery Rate; FWE-corr, corrected for Family-Wise Error; SPECT, single-photon emission computed tomography;
SPM, Statistical Parametric Mapping.
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The CBS and VHF-DLB groups did not differ on MMSE
or DRS, suggesting that they were well-matched for de-
mentia severity, which was in the mild stages in both
groups. Both patient groups also had a similar duration of
disease at the time of investigation, therefore, making it
unlikely to be a confounding factor.
CBS and DLB groups often exhibit primarily executive
dysfunction greater than memory impairment, exempli-
fied by disproportionate deficits when performing the
WCST, Stroop test, TMT, and Delis-Kaplan Executive
Function System [57-60]. Visuospatial dysfunction has
also been shown to be disproportionately severe in DLB
patients, when assessed using standardised measures
such as the Benton Judgment of Line Orientation (BJLO)
or the Rey-Ostereith Complex Figure Copy Paradigm
(ROCF-CP) [61]. Such deficits have been attributed to
problems with perceptual processing and apraxia in DLB
patients [62,63]. When compared to PSP and Multiple
System Atrophy (MSA), CBS has been shown to have the
most consistent and severe impairment of visuospatial
function on the BJLO and the Visual Object and SpacePerception Battery (VOSP) [64,65]. Indeed, tests assessing
general cognition, attention and working memory, execu-
tive functions, language, praxis and visuospatial abilities
did not distinguish between the VHF-DLB and CBS
groups included in this study indicating substantial over-
lap in their overall clinical neuropsychological profiles.
The CVLT is a standardized and validated test of verbal
episodic memory function and is a widely used measure in
the dementia literature [66]. Our results suggest that al-
though CBS and VHF-DLB patients both benefit similarly
from cueing, indicating that frontal-subcortical dysfunc-
tion contributes to their memory deficits, the VHF-DLB
group recalled fewer words overall compared to the CBS
group. This may be due to more severe encoding versus
retrieval problems in the VHF-DLB group. The sum of the
total number of words retained after learning trials, one
through five, was significantly lower in the VHF-DLB
group suggesting that this group had more troubles with
encoding than the CBS group. This may be due to con-
comitant AD pathology in the VHF-DLB group, which is
consistent with prior studies showing significant patho-
logical overlap between DLB and AD [1] as well as the
Table 6 Areas of relative hypoperfusion on SPECT when VHF-DLB is compared to their respective control group
Anatomical locus (Brodmann area) Talairach coordinates Number of voxels SPM t-score (P-value)
x y z
VHF-DLB versus controls (FWE-corr)
Left middle temporal gyrus (21) −57 −49 −3 413 6.2 (P =0.000)
Right middle temporal gyrus (39) 44 −63 31 1292 5.9 (P =0.001)
Right superior parietal lobule (7) 30 −64 46 5.6 (P =0.003)
Left precuneus (19) −34 −64 42 1195 5.9 (P =0.001)
Left superior temporal gyrus (39) −48 −57 27 5.7 (P =0.002)
Left inferior parietal lobule (40) −46 −56 39 5.5 (P =0.004)
Right middle temporal gyrus (21) 61 −35 −10 211 5.4 (P =0.005)
Left middle occipital gyrus −28 −89 −2 100 5.1 (P =0.013)
VHF-DLB versus controls (FDR-corr)
Left middle frontal gyrus (21) −57 −49 −3 33550 6.2 (P =0.000)
Left precuneus (19) −34 −64 42 5.9 (P =0.000)
Right middle temporal gyrus (39) 44 −63 31 5.9 (P = 0.000)
Right middle frontal gyrus (8) 36 16 45 1743 3.9 (P =0.002)
Right middle frontal gyrus (9) 36 27 37 3.9 (P =0.002)
Right superior frontal gyrus (8) 20 39 39 3.7 (P =0.003)
Left medial frontal gyrus (11) −4 61 −15 144 3.7 (P =0.003)
Right inferior frontal gyrus (47) 50 27 −3 344 3.6 (P =0.004)
Left sub-lobar caudate −14 10 5 41 3.4 (P =0.006)
Right superior frontal gyrus (9) 14 52 25 23 3.2 (P =0.008)
FDR-corr ,corrected for False Discovery Rate; FWE-corr, corrected for Family-Wise Error; SPECT, single-photon emission computed tomography; SPM, Statistical Para-
metric Mapping; VHF-DLB, visual hallucination-free dementia with Lewy bodies.
Misch et al. Alzheimer's Research & Therapy 2014, 6:71 Page 11 of 15
http://alzres.com/content/6/9/71finding that three of our VHF-DLB cases that came to aut-
opsy all demonstrated concomitant DLB, AD as well as ar-
teriosclerosis. While the inclusion of possible VHF-DLB
cases increases the likelihood that these patients may have
AD pathology and not DLB, the fact that all of our VHF-
DLB cases had parkinsonism makes pure AD pathology
very unlikely in this patient group.
The SPECT data showed typical perfusion profiles of
CBS [67-70] and DLB [46], as demonstrated in prior
studies. This strongly supports that our patient groups
were similar to other published case series and improves
on diagnostic accuracy. Areas of relative hypoperfusion
have been found to involve frontal and parietal regions
in both DLB and CBS [46,69,71]. While bilateral perfu-
sion deficits are characteristic of DLB [72], CBS patients
tend to show asymmetrical perfusion syndromes in most
[71,73], but not all, studies [69]. These prior studies
demonstrate overlap in the hypoperfused brain regions
found on SPECT in both DLB and CBS.
Reduced perfusion in the left occipital pole ROI was ob-
served in the VHF-DLB group compared to the CBS
group, while there were no brain ROIs with significantly
reduced perfusion observed in the CBS relative to the
VHF-DLB group. Occipital hypoperfusion most pro-
nounced at the parieto-occipital junction on SPECT is awell-known feature of DLB [46,72] and is one of the sup-
portive features in the consensus diagnostic criteria [9].
Occipital lobe dysfunction in DLB was first demonstrated
using fluoro-deoxyglucose positron emission tomography
(FDG-PET) [74,75]. It was later shown that occipital lobe
abnormalities could be used to differentiate DLB from
AD, with a sensitivity and specificity ranging as high as
92% for both [76-78]. Subsequently, occipital lobe dys-
function was confirmed using SPECT tracers including
I-labelled isopropyl-iodoamphetamine SPECT [79] and
99 m Tc-HMPAO SPECT [80]. Pasquier et al. [81] dem-
onstrated decreased bilateral occipital lobe perfusion in
DLB as compared to AD using 99 m Tc-ECD SPECT. Bi-
lateral occipital lobe hypoperfusion in combination with
maintained perfusion within the left internal temporal re-
gion has been shown to favour a diagnosis of DLB over
AD with 65% sensitivity and 71% specificity [81,82].
The left occipital pole ROI in our SPECT template con-
tained 712 voxels, mainly in BA 18 and part of BA 17,
comprising secondary visual association and the primary
visual cortices, respectively. This ROI includes the follow-
ing neuroanatomical structures that function together to
interpret the visual world: cuneus, lingual gyrus and lateral
occipital gyrus. A more conservative SPM analysis con-
firmed that the left cuneus showed significant reductions
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patients. The cuneus is involved in primary visual process-
ing, particularly in integrating ocular position signals to
process stimuli position in space [83]. It has also been
shown to have a variety of roles within the cognitive do-
main, including response inhibition [84], working memory
[85] and behavioural engagement in cognitive control [86].
The lingual gyrus is involved in visual memory [87], en-
coding of complex images [88] and identification/recogni-
tion of letters and words [89,90]. A more recent resting
state functional MRI study also identified a role of the bi-
lateral lingual gyri in object colour knowledge [91,92]. The
lateral occipital complex may play an important role in
the recognition and perception of objects [93]. Many of
these processes are selectively impaired in individuals suf-
fering from DLB.
Our study had both strengths and limitations that war-
rant discussion. A main strength was our relatively large
sample size given the rarity of both diagnostic groups in-
cluded. An important limitation is the lack of pathological
confirmation in the majority of our cases. However, a por-
tion of each group was confirmed with the predicted path-
ology. All three of the VHF-DLB cases were confirmed to
have DLB, and six of the nine CBS subjects autopsied had
pathologic verification of CBD, a ratio consistent with pre-
vious studies [5]. The remaining CBS cases had pathology
recognized to cause a CBS and none had additional Lewy
body or other alpha-synuclein-related pathology. To over-
come the lack of pathological confirmation in our sample,
we chose as a first step in this line of investigation to
include individuals meeting consensus diagnostic criteria
for CBS and VHF-DLB. We acknowledge that this may
reduce the chances that our findings are generalisable to
earlier clinical stages of VHF-DLB and CBS. Therefore, we
will plan to validate our findings in an independent cohort
of pathologically confirmed cases that is being ascertained
with both diagnoses and that have been followed from
early stages using CVLT and brain SPECT when they are
particularly hard to distinguish from each other. Thus,
these results represent the first phase of an ongoing pro-
ject. Importantly though, we demonstrate that many of
the VHF-DLB patients have overlapping clinical features
with the CBS group and vice versa. An additional limita-
tion is the reduced statistical power for the neuroimaging
analyses, which is likely the reason why the perfusion dif-
ferences between the VHF-DLB and CBS groups localised
only to the left occipital region and not to the correspond-
ing contralateral side and why the MRI volumetric and
thickness measures did not show any differences between
the patient groups. This is especially the case for the ana-
lysis of MRI data as there were only 21 useable MRIs in
the CBS group and 23 in the VHF-DLB group. Despite this
limitation, our results suggest that perfusion measures may
be more sensitive than atrophy measures in syndromes thathave some degree of clinical overlap. This is supported by
prior research of focal cortical atrophy syndromes, such as
FTLD, whereby perfusion reductions on SPECT are more
extensive than atrophy detected on MRI in the early stages
of disease and in longitudinal follow-up, indicating in-
creased sensitivity of this modality as a potential bio-
marker [94-96].
Conclusions
In spite of the limited pathology available, the benefit of
our study is that it provides neuropsychological and neu-
roimaging features useful for differentiating VHF-DLB
and CBS in the antemortem period. Indeed, the diagnos-
tic challenges faced by clinicians are in the antemortem
period, when only syndromic presentations, and a lack
of any pathological verification, are available to inform
their diagnostic considerations. Our segregation of VHF-
DLB and CBS groups, based on expert consensus and
strongly supported by SPECT perfusion profiles, repre-
sents the same information that clinicians will need to
rely on to inform treatment decisions, without the guid-
ance of pathology. Therefore, our study provides clini-
cians with information they can use in difficult cases to
help support diagnostic stratification and treatment
plans for these two overlapping clinical entities.
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